ALPHARETTA, Ga.--(BUSINESS WIRE)--June 14, 2006--First Horizon Pharmaceutical Corporation (NASDAQ:FHRX - News) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's glycopyrrolate, which is used to treat chronic moderate to severe drooling in pediatric patients. This condition often results from cerebral palsy and other neurological disorders. The Company currently is conducting clinical trials for this indication. Glycopyrrolate, an anticholinergic agent, also is approved as an adjunctive therapy in the treatment of peptic ulcers.
